Business Wire

NY-SER-CAPITAL-PARTNERS

13.9.2022 12:01:49 CEST | Business Wire | Press release

Share
SER Capital Partners Closes Debut Fund, Raises $475 Million

SER Capital Partners (SER), a private investment firm dedicated to sustainability, today announced the final closing of its SER Capital Partners I, LP and affiliated vehicles. SER raised a total of $475 million in support of its strategy to meaningfully capitalize middle-market businesses and infrastructure assets. SER’s inaugural fundraise exceeded its stated target with the support of aligned and well-capitalized limited partners that include a diverse group of leading endowments, state pensions, insurers, health systems and family offices.

SER invests and enhances value in businesses positioned to meet the growing demand for economic and sustainable assets, products, and services across North America. SER is led by four partners – Rahul Advani, Sara Graziano, Christopher Smith and Rhem Wooten – who bring meaningful overlapping experiences to SER. Each has successfully pioneered sustainability-focused investments and held key executive operating roles at public and private businesses over the last two decades.

“We collectively built SER to meet the critical market need for an experienced and aligned private investment firm dedicated to sustainable, environmental and renewable sectors,” said Rahul Advani, SER’s founder and Managing Partner. “We are committed to economically meeting the burgeoning customer demand for decarbonized, distributed, digitized, and electrified solutions.”

SER has already directly originated investments in four portfolio companies. These businesses collectively implement and manage battery storage, EV charging infrastructure, energy efficiency and solar assets.

  • Microgrid Networks, one of SER’s portfolio companies, helps meet New York City’s critical infrastructure needs by developing and installing battery storage assets coupled with related infrastructure, such as high-speed electric vehicle charging capabilities.
  • Perfect Power, a fast-growing energy storage and renewable development business formed by SER, is active in high-demand markets across the United States.
  • Brightcore Energy, a leading provider of end-to-end clean energy solutions to the commercial and institutional market, is using SER’s investment to better enable it to help buildings transition legacy energy platforms to significantly more efficient ones.
  • SER also developed and built a portfolio of Texas battery storage assets that it exited in an M&A transaction earlier this year.

“Looking ahead, we see a myriad of compelling investment opportunities that move us beyond legacy industrial processes heavily reliant on fossil fuels and subject to extreme commodity volatility – including those benefitting from the supportive patchwork of local, state, regional and recently expanded federal policies. Importantly, we are enthusiastic about our ability to invest in teams, businesses and assets that are poised to deliver attractive returns and protect our energy security and climate future,” Advani continued.

Metric Point Capital, a boutique private capital advisory firm, served as the placement agent. DLA Piper represented SER in connection with the fund formation.

About SER Capital Partners
SER Capital Partners is an independent, middle-market private equity firm dedicated to investing in North American sustainable industrial, environmental, and renewable businesses. Over the past two decades, its team members have amassed successful experience in its targeted sectors as private equity investors and senior executives at both private and public businesses. The firm’s strategy is to actively create attractive investments underpinned by critical assets while also authentically measuring and improving key sustainability metrics in line with the UN Principles for Responsible Investing. SER is also committed to aligning interests across its investors, team members, portfolio company management teams, and communities. More is available at www.sercapitalpartners.com.

About Metric Point Capital (Member FINRA and SIPC)
Metric Point is a boutique private capital advisory firm that specializes in raising institutional capital and executing transactions across the full spectrum of primaries, secondaries, and other liquidity solutions for alternative investment managers.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220913005474/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Inspirit Capital to Acquire Kaplan Languages Group20.4.2026 17:15:00 CEST | Press release

Inspirit Capital, a specialist investor in corporate carve-outs, is pleased to announce its plans to acquire KLG Kaplan Languages Group (“KLG”), a leading global language education platform, from Kaplan. All conditions for the sale have been met, and completion is due to take place on 1 May. KLG comprises Kaplan International Languages, Alpadia Language Schools, Azurlingua, and ESL Education. Since 2006, KLG has provided high-quality language education, supporting students in achieving their language goals through academic excellence, cultural immersion, and life-changing experiences. Inspirit Capital will support KLG in delivering on its ambitious growth plans, whilst continuing its fundamental mission to transform lives through language education. This next phase of ownership will also see the development of a refreshed standalone brand identity for KLG, with further announcements to follow on this in due course. Paul Youens, Investment Director, Inspirit Capital: “KLG has built a st

Cleaner by Design: SaniSure Introduces PETG PharmaTainer™ Ultra-Clean Bottles & Carboys20.4.2026 16:00:00 CEST | Press release

Industry’s most widely adopted PETG material meets industry-leading cleanliness, compliance, and RNase/DNase-free validation—now available across the full bioprocessing workflow. SaniSure® today announced the launch of PETG PharmaTainer™, a new line of bioprocessing bottles and carboys combining widely accepted, medical-grade Eastman Eastar® PETG 6763 resin (DMF#9987) with SaniSure’s proprietary process and advanced automation. This launch expands SaniSure’s established PharmaTainer® platform—extending its proven cleanliness, robustness, and performance attributes to include industry-standard PETG alongside its existing PET and PC offerings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260420641769/en/ PETG PharmaTainer™ bottles and carboys—RNase/DNase-free, ultra-clean, ready-to-use containers for bioprocessing applications. Available in volumes from 10 mL stability vials to 10 L carboys — in sterile (gamma-irradiated) an

Leaders of Dubai-Based Unicorns Hail City as Global Innovation Hub Shaping Future Technology and Driving the Digital Economy20.4.2026 15:08:00 CEST | Press release

Leaders of Dubai-based unicorn companies have reaffirmed the emirate’s status as a global hub for digital innovation and technology-led growth. The senior executives highlighted Dubai’s forward-looking regulatory environment, advanced infrastructure, and ability to attract international talent as key factors strengthening its appeal for high-growth digital businesses. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260420503062/en/ Leaders of Dubai-based unicorns hail city as global innovation hub shaping future technology and driving the digital economy (Photo: AETOSWire) They noted that Dubai has evolved into a strategic launchpad for ambitious companies, offering an agile business environment that supports innovation and enables expansion into regional and international markets. The business leaders also praised the strong alignment between the public and private sectors within Dubai’s digital ecosystem, supported by Dubai

Capcom’s All-New IP PRAGMATA Surpasses One Million Units Sold in Two Days!20.4.2026 15:00:00 CEST | Press release

– Highly innovative and original gameplay earns strong reception from players around the globe – Capcom Co., Ltd. (TOKYO:9697) today announced that worldwide sales of PRAGMATA, the company’s all-new IP released on April 17, 2026*, have surpassed one million units. PRAGMATA is a science-fiction action-adventure game that depicts the journey of Hugh Williams and Diana, an android girl, in a near-future lunar world. A completely new IP, PRAGMATA was developed primarily by a team of younger Capcom developers, who created an innovative gameplay experience by fusing action gameplay with puzzle elements set within a distinctive world ruled over by artificial intelligence. In the absence of an established fan base or preexisting brand recognition, Capcom implemented a range of marketing initiatives—beginning with the early release of a playable demo—to communicate the unique features of the game to a wider audience. In addition, in line with the company’s multi-platform strategy, Capcom broade

Following Oral Presentation of Phase I Data at AACR 2026, Debiopharm Announces FDA Fast Track Designation for Lunresertib in Combination With Zedoresertib for Genomic-Defined Platinum-Resistant Ovarian Cancer20.4.2026 14:30:00 CEST | Press release

Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard of care to cure cancer and infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the combination of its PKMYT1 inhibitor, lunresertib (Debio2513), and its WEE1 inhibitor, zedoresertib (Debio 0123). The designation is for the treatment of adult patients with CCNE1 amplified, or a deleterious mutation in either FBXW7 or PPP2R1A, platinum-resistant/refractory ovarian cancer. The FDA’s Fast Track program is designed to facilitate the development and expedite the review of new drugs intended to treat serious conditions and fill an unmet medical need. Programs granted Fast Track designation benefit from more frequent communication with the FDA and, if relevant criteria are met, may be eligible for Priority Review and Accelerated Approval of a New Drug Application (NDA). Momentum Following AACR O

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye